MedTech Ventures

MedTech Ventures is a San Francisco-based venture capital firm that has built its reputation around a specific, disciplined focus: medical device companies navigating the FDA clearance process. Unlike generalist healthcare investors, MedTech Ventures targets the gap between proof-of-concept and commercial launch, making them a natural fit for founders who have validated their technology but need capital to complete regulatory pathways and early market entry.

The firm manages $380 million across two funds and has deployed capital into 24 medical device companies since its founding in 2015. Their portfolio skews heavily toward cardiovascular, orthopedic, and diagnostic devices, with several companies having achieved 510(k) clearance or FDA PMA approval under their investment tenure.

What sets MedTech Ventures apart is their operational approach. The firm employs two former FDA regulators as part-time advisors and has deep relationships with the FDA's Center for Devices and Radiological Health (CDRH). For founders navigating the notoriously complex 510(k) and PMA processes, this regulatory intelligence can be as valuable as the capital itself.

MedTech Ventures typically writes first checks between $2 million and $8 million, preferring to reserve capital for follow-on rounds as companies hit regulatory milestones. This reserve-heavy approach reflects their thesis that medical device companies require patient capital through regulatory hurdle, not just initial funding.

The firm's portfolio includes companies at various stages of the FDA journey, from pre-submission feasibility through early commercial launch. This allows MedTech Ventures to match its expertise with companies at the precise stage where their insights create the most value.

MedTech Ventures operates from a straightforward conviction: the most undervalued moment in a medical device company's lifecycle is the period between prototype validation and FDA clearance. Most VCs either invest too early (at the concept stage, where regulatory risk is unquantifiable) or too late (at commercial scale, where valuation premiums eliminate upside). MedTech Ventures positions itself squarely in the middle.

The firm's investment thesis centers on three pillars. First, they seek companies with a clearly defined regulatory pathway—either a 510(k) predicate device strategy or a PMA with a defined clinical trial endpoint. They avoid companies whose regulatory path is ambiguous or requires de novo classification without clear precedent.

Second, MedTech Ventures looks for devices that address large market opportunities with clear reimbursement codes. They particularly favor procedures with established CPT codes and DRG groupings, where the reimbursement landscape is predictable. A device that requires novel coding or extensive health economics data before adoption represents too much execution risk for their taste.

Third, they prioritize companies where the founding team includes at least one person with prior FDA experience or a clinical advisor who has shepherded devices through the clearance process before. MedTech Ventures views regulatory expertise as a leading indicator of execution capability.

The firm explicitly avoids digital health companies unless they are paired with a hardware component, and they steer clear of biotechnology and pharmaceuticals entirely. This narrow focus allows the partners to develop genuine domain expertise rather than spreading their attention across healthcare verticals.

Geographically, MedTech Ventures concentrates on companies based in the United States, Canada, and Israel. European companies are considered on a case-by-case basis, typically when they have a clear US market entry strategy and have secured FDA pre-submission feedback.

MedTech Ventures has maintained a consistent deployment pace over the past three years, completing 6 to 8 new investments annually. The firm has been particularly active in electrophysiology and catheter-based delivery systems, areas where they see significant unmet need and relatively predictable regulatory pathways.

In 2025, MedTech Ventures led the $12 million Series B for Cordixx, a catheter ablation company developing pulsed field ablation technology for atrial fibrillation. The investment came after Cordixx received FDA 510(k) clearance and needed capital to build out its commercial infrastructure. MedTech Ventures partner Dr. Sarah Chen joined the board as part of the transaction.

The firm also participated in a $7.5 million Series A for VeraCartilage, a company developing an autologous chondrocyte implantation device for knee cartilage repair. VeraCartilage had completed a successful feasibility study and was preparing for its FDA pre-submission meeting when MedTech Ventures led the round.

MedTech Ventures's 2024 portfolio activity included two follow-on investments in existing holdings. CardiacBridge, a company developing embolic protection devices for transcatheter aortic valve replacement (TAVR) procedures, raised a $15 million Series C with MedTech Ventures contributing $5 million. The round values the company at approximately 4.5x its Series B valuation, reflecting meaningful de-risking following positive six-month clinical data.

The firm has been selective about market conditions, passing on several opportunities in 2024 where valuation expectations did not align with their risk-adjusted return requirements. MedTech Ventures managing partner David Okafor has publicly noted that the firm is willing to wait for the right price rather than forcing deployment.

Looking ahead, MedTech Ventures has indicated interest in expanding its portfolio into neuromodulation and generative surgery, areas where they see large markets and relatively predictable regulatory frameworks based on existing device precedents.

MedTech Ventures's portfolio reflects its thematic focus on FDA-stage medical devices. Several portfolio companies have achieved notable regulatory milestones and are progressing toward commercial adoption.

Cordixx, based in Minneapolis, Minnesota, is developing pulsed field ablation catheters for the treatment of atrial fibrillation. The company received FDA 510(k) clearance in early 2025 and is currently building its direct sales force in preparation for a full US commercial launch. MedTech Ventures led the company's $12 million Series B and holds a board seat.

CardiacBridge specializes in embolic protection devices designed to reduce stroke risk during TAVR procedures. The company's Sentinel device has been used in over 3,000 procedures across 40 US centers, with data published in the Journal of the American College of Cardiology. CardiacBridge is preparing for a Series C extension to fund international expansion into European markets.

VeraCartilage is a Boston-based company developing a next-generation autologous chondrocyte implantation system for knee cartilage defects. The device offers a less invasive collection method compared to existing options and is currently in a pivotal trial expected to support a 510(k) submission in 2027.

Other portfolio companies include Aortha Medical (shoulder replacement implants), NervaTech (deep brain stimulation leads), and Pulse Diagnostics (point-of-care sepsis screening platform). Each of these companies is at a different stage of the FDA process, providing MedTech Ventures with a portfolio-level view across the regulatory lifecycle.

Notable exits from the MedTech Ventures portfolio include Vascular Solutions (acquired by Boston Scientific for $280 million in 2019), Endotemperature (acquired by Medtronic for $180 million in 2021), and OrthoFix (IPO on Nasdaq, 2023, current market cap of approximately $890 million).

The diversity of exit outcomes—strategic acquisitions and an IPO—reflects MedTech Ventures's thesis that medical device companies can generate returns through multiple paths, depending on competitive dynamics and strategic fit with acquirers.

MedTech Ventures evaluates potential investments through a rigorous regulatory and commercial lens. Understanding what the firm prioritizes can significantly improve a founder's odds of securing a meeting.

The single most important factor is regulatory pathway clarity. MedTech Ventures wants to see that founders have already engaged with the FDA and received documented feedback—whether through a pre-submission meeting, Q-sub process, or informal interaction. Companies that have not yet had regulatory feedback are considerably less attractive, as the uncertainty premium is too high for the firm's risk tolerance.

Market size and reimbursement specificity matter significantly. MedTech Ventures prefers companies addressing procedures with established CPT codes and favorable Medicare DRG assignments. A device requiring a new CPT code application faces a 12 to 24 month reimbursement delay that can cripple commercial execution, and MedTech Ventures explicitly factors this into their valuation models.

The founding team's regulatory experience is a major positive signal. MedTech Ventures is particularly interested in companies where a founder or key advisor has previously guided a device through the FDA process from submission to clearance. First-time device founders are not disqualified, but they need to demonstrate strong institutional partnerships or advisory relationships that弥补 their inexperience with the regulatory process.

Clinical data quality matters more than quantity at the investment stage. MedTech Ventures looks for studies that are prospectively designed, adequately powered for their stated endpoint, and conducted at sites with strong investigator experience. Retrospective data from a small number of cases is viewed skeptically unless it is clearly framed as feasibility work that informs a rigorous pivotal study design.

Intellectual property is evaluated carefully but not treated as the primary value driver. MedTech Ventures recognizes that many medical device patents are easily designed around and that FDA clearance itself creates a meaningful barrier to entry. The firm focuses on whether the company's IP position provides at least 3 to 5 years of runway before meaningful generic or biosimilar competition could emerge.

Finally, MedTech Ventures looks for realistic capitalization tables. Companies that have raised too much at too high a valuation before regulatory milestones—creating unrealistic expectations for future rounds— are structurally problematic for the firm's return profile.

MedTech Ventures is accessible primarily through warm introductions, and the firm has built its deal flow around a network of referring sources rather than open submission processes. Understanding how to navigate this dynamic is essential for founders seeking a meeting.

The most effective intro pathway is through MedTech Ventures's portfolio company founders. The firm is transparent that they give meaningful preference to referrals from existing holdings, who can speak to both the company's progress and the partnership experience. Founders who have worked with MedTech Ventures and can vouch for the firm's operational value are credible endorsers.

Medical professional referrals carry significant weight. Surgeons, interventional cardiologists, and other clinical thought leaders who have interacted with a company and can speak to its clinical merit provide a powerful signal. MedTech Ventures maintains relationships with several key opinion leaders (KOLs) who occasionally facilitate introductions to companies they believe in.

Fellow investors are another important channel. MedTech Ventures co-invests regularly with a small group of peer funds, and founders who have already secured commitment from a recognized co-investor often find the due diligence process moves faster. The firm respects founders who demonstrate the ability to build a coalition of supporters.

Cold outreach is accepted but less effective. MedTech Ventures's website lists a submission email for companies that do not have existing relationships. The firm's investment team reviews submissions, but the response rate for cold inbound applications is notably lower than for warm introductions. Founders pursuing cold outreach should lead with regulatory status and clinical data in the subject line.

Conference engagement is part of MedTech Ventures's deal sourcing strategy. The firm is an active participant at the AdvaMed Innovators Conference, the American College of Cardiology (ACC) annual meeting, and the TCT (Transcatheter Cardiovascular Therapeutics) conference. Founders presenting at or attending these events can often arrange brief introductory meetings during conference weeks.

Following up after an initial conversation is expected and appropriate. MedTech Ventures moves deliberately, and founders should not interpret a lack of immediate response as disinterest. Sending brief updates on regulatory milestones, clinical enrollment milestones, or new data publications demonstrates momentum and keeps the company on the firm's radar.

While MedTech Ventures invests at a stage where revenue is often minimal or nonexistent, they expect founders to have a sophisticated understanding of their financial model and a realistic view of their capital requirements through regulatory clearance and early commercialization.

The firm pays particular attention to the use of funds. MedTech Ventures expects detailed, milestone-based financial models that map capital deployment to specific regulatory and clinical achievements. A budget that simply allocates spending across general categories—without linking expenditures to verifiable milestones— signals insufficient operational rigor.

Medical device founders should be prepared to discuss their reimbursement strategy in detail. MedTech Ventures wants to understand not just the clinical value proposition but the economic case: How will the device be coded? What is the expected hospital margin? Has a health economic analysis been conducted to support the value story for hospital value analysis committees?

The burn rate profile for medical device companies is different from software startups. MedTech Ventures recognizes that regulatory and clinical expenses can be lumpy and unpredictable, and they value founders who can articulate this nuance. However, they also expect tight operational discipline, particularly around headcount and clinical trial costs.

Working with a fractional CFO who understands the medical device industry can meaningfully improve a company's positioning with MedTech Ventures. A financial partner who can present the business model, reimbursement pathway, and capital requirements in investor-ready format demonstrates a level of professionalism that differentiates serious founders from those who are less prepared.

Our team has deep experience helping medical device companies prepare for venture capital fundraising. We understand what MedTech Ventures looks for in financial presentations and can help you build the narratives—around regulatory risk, reimbursement strategy, and milestone-based capital needs—that resonate with medical device investors.

Financial projections for FDA-stage companies should be grounded in actual clinical data where available, and clearly labeled as assumptions where they are forward-looking. MedTech Ventures distinguishes carefully between validated data and speculative forecasts, and founders who blur this line lose credibility quickly.

Whether you are preparing for your first conversation with MedTech Ventures or refining your approach for an upcoming fundraise, professional financial modeling and investor-ready presentations can meaningfully improve your positioning. Our team works specifically with medical device and health tech founders to build the financial narratives that resonate with FDA-stage investors.

Exploring other venture capital firms with specific healthcare or medical device focus? Our comprehensive collection of VC firm reviews covers investors across all stages and sectors.

Each review provides detailed information about investment criteria, portfolio companies, and strategies for securing funding from firms that match your company's stage and sector focus.

Finding an investor whose thesis aligns with your company's regulatory pathway and market opportunity is one of the most important decisions you'll make in building your cap table.

Our guides cover major medical device-focused VCs, growth equity firms, and corporate venture arms of leading health systems and medical device companies.